Syncona: investor interest is exploding in this area of science
Martin Murphy explains why his life sciences investment business has been so successful.
18th November 2020 11:47
by Lee Wild from interactive investor
Martin Murphy, co-founder of Syncona (LSE:SYNC), one of interactive investor’s ACE 40 rated ethical funds, explains to us why his life sciences investment business has been so successful, the companies he invests in and what makes them so special.
- Explore more fund manager interviews on our YouTube channel
- Want to invest ethically? ii’s ACE 40 list of ethical investments can help
Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.
These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.